文献速递甲状腺疾病

左甲状腺素治疗对老年亚临床甲减患者动脉粥样硬化的影响:一项随机试验

Impact of Thyroid Hormone Therapy on Atherosclerosis in the Elderly With Subclinical Hypothyroidism: A Randomized Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

中位治疗18.4个月后,左甲状腺素组与安慰剂组在颈动脉内膜中层厚度、斑块比例及最大斑块厚度上均无显著差异。

要点

  • 左甲状腺素使TSH正常化未显著改变老年亚临床甲减患者的颈动脉内膜中层厚度。
  • 左甲状腺素组与安慰剂组的颈动脉斑块比例及最大斑块厚度均无显著差异。
  • 按性别、基线TSH分层或已有心血管病分层的交互作用均不显著。

核心结论

  • 在老年亚临床甲减患者中,左甲状腺素使TSH正常化与颈动脉内膜中层厚度及颈动脉粥样硬化无差异相关。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,嵌套于甲状腺激素替代治疗亚临床甲减试验(TRUST)。

主要发现

  • 基线平均TSH±SD为6.35±1.95 mIU/L;左甲状腺素组降至3.55±2.14 mIU/L,安慰剂组为5.29±2.21 mIU/L(P < 0.001)。
  • 中位治疗18.4个月(四分位距12.2至30.0个月)后,平均CIMT左甲状腺素组为0.85±0.14 mm,安慰剂组为0.82±0.13 mm(组间差异=0.02 mm;95% CI,-0.01至0.06;P = 0.30)。
  • 颈动脉斑块比例相似:左甲状腺素组70.8%(n=135),安慰剂组75.3%(P = 0.46)。
  • 最大颈动脉斑块厚度左甲状腺素组为2.38±0.92 mm,安慰剂组为2.37±0.91 mm(组间差异-0.03;95% CI,-0.34至0.29;P = 0.86)。
  • 左甲状腺素治疗与平均CIMT之间,按性别、基线TSH分层(4.6至6.9、7.0至9.9、≥10 mIU/L)或已有心血管病分层的交互作用均不显著(所有交互作用P ≥ 0.14)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Subclinical hypothyroidism (SHypo) has been associated with atherosclerosis, but no conclusive clinical trials assessing the levothyroxine impact on carotid atherosclerosis exist. OBJECTIVE: To assess the impact of treatment of SHypo with levothyroxine on carotid atherosclerosis. DESIGN AND SETTING: Randomized, double-blind, placebo-controlled trial nested within the Thyroid Hormone Replacement for Subclinical Hypothyroidism trial. PARTICIPANTS: Participants aged ≥65 years with SHypo [thyroid-stimulating hormone (TSH), 4.60 to 19.99 mIU/L; free thyroxine level within reference range]. INTERVENTION: Levothyroxine dose-titrated to achieve TSH normalization or placebo, including mock titrations. MAIN OUTCOME MEASURES: Carotid intima media thickness (CIMT), maximum plaque thickness measured with ultrasound. RESULTS: One hundred eighty-five participants (mean age 74.1 years, 47% women, 96 randomized to levothyroxine) underwent carotid ultrasound. Overall mean TSH ± SD was 6.35 ± 1.95 mIU/L at baseline and decreased to 3.55 ± 2.14 mIU/L with levothyroxine compared with 5.29 ± 2.21 mIU/L with placebo (P < 0.001). After a median treatment of 18.4 months (interquartile range 12.2 to 30.0 months), mean CIMT was 0.85 ± 0.14 mm under levothyroxine and 0.82 ± 0.13 mm under placebo [between-group difference = 0.02 mm; 95% CI, -0.01 to 0.06; P = 0.30]. The proportion of carotid plaque was similar (n = 135; 70.8% under levothyroxine and 75.3% under placebo; P = 0.46). Maximum carotid plaque thickness was 2.38 ± 0.92 mm under levothyroxine and 2.37 ± 0.91 mm under placebo (between-group difference -0.03; 95% CI, -0.34 to 0.29; P = 0.86). There were no significant interactions between levothyroxine treatment and mean CIMT, according to sex, baseline TSH (categories 4.6 to 6.9, 7.0 to 9.9, and ≥10 mIU/L), or established cardiovascular disease (all P for interaction ≥ 0.14). CONCLUSION: Normalization of TSH with levothyroxine was associated with no difference in CIMT and carotid atherosclerosis in older persons with SHypo.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Blum MR, Gencer B, Adam L, et al. Impact of Thyroid Hormone Therapy on Atherosclerosis in the Elderly With Subclinical Hypothyroidism: A Randomized Trial. J Clin Endocrinol Metab. 2018. PMID: 29846630. doi:10.1210/jc.2018-00279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。